PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Gilead Sciences, Inc. (GILD)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS3755581036
CUSIP375558103
SectorHealthcare
IndustryDrug Manufacturers—General

Highlights

Market Cap$83.25B
EPS$4.50
PE Ratio14.84
PEG Ratio0.42
Revenue (TTM)$27.12B
Gross Profit (TTM)$21.62B
EBITDA (TTM)$12.49B
Year Range$65.90 - $86.98
Target Price$84.40
Short %1.81%
Short Ratio3.06

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Gilead Sciences, Inc.

Popular comparisons: GILD vs. AMGN, GILD vs. BMY, GILD vs. VOO, GILD vs. ABBV, GILD vs. PEP, GILD vs. VTI, GILD vs. LLY, GILD vs. JNJ, GILD vs. ^SP500TR, GILD vs. MRK

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Gilead Sciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%NovemberDecember2024FebruaryMarchApril
-12.00%
18.82%
GILD (Gilead Sciences, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Gilead Sciences, Inc. had a return of -16.51% year-to-date (YTD) and -19.62% in the last 12 months. Over the past 10 years, Gilead Sciences, Inc. had an annualized return of 2.11%, while the S&P 500 had an annualized return of 10.42%, indicating that Gilead Sciences, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-16.51%5.05%
1 month-7.80%-4.27%
6 months-12.00%18.82%
1 year-19.62%21.22%
5 years (annualized)5.49%11.38%
10 years (annualized)2.11%10.42%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-3.39%-7.87%2.64%
2023-1.05%4.80%-2.47%6.72%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of GILD is 12, indicating that it is in the bottom 12% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of GILD is 1212
Gilead Sciences, Inc.(GILD)
The Sharpe Ratio Rank of GILD is 1111Sharpe Ratio Rank
The Sortino Ratio Rank of GILD is 1616Sortino Ratio Rank
The Omega Ratio Rank of GILD is 1515Omega Ratio Rank
The Calmar Ratio Rank of GILD is 1313Calmar Ratio Rank
The Martin Ratio Rank of GILD is 55Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


GILD
Sharpe ratio
The chart of Sharpe ratio for GILD, currently valued at -0.82, compared to the broader market-2.00-1.000.001.002.003.00-0.82
Sortino ratio
The chart of Sortino ratio for GILD, currently valued at -1.00, compared to the broader market-4.00-2.000.002.004.00-1.00
Omega ratio
The chart of Omega ratio for GILD, currently valued at 0.87, compared to the broader market0.501.001.500.87
Calmar ratio
The chart of Calmar ratio for GILD, currently valued at -0.67, compared to the broader market0.001.002.003.004.005.00-0.67
Martin ratio
The chart of Martin ratio for GILD, currently valued at -1.56, compared to the broader market0.0010.0020.0030.00-1.56
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.81, compared to the broader market-2.00-1.000.001.002.003.001.81
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.64, compared to the broader market-4.00-2.000.002.004.002.64
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.32
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.001.002.003.004.005.001.38
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current Gilead Sciences, Inc. Sharpe ratio is -0.82. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.82
1.81
GILD (Gilead Sciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History

Gilead Sciences, Inc. granted a 4.51% dividend yield in the last twelve months. The annual payout for that period amounted to $3.02 per share.


PeriodTTM202320222021202020192018201720162015
Dividend$3.02$3.00$2.92$2.84$2.72$2.52$2.28$2.08$1.84$1.29

Dividend yield

4.51%3.70%3.40%3.91%4.67%3.88%3.65%2.90%2.57%1.27%

Monthly Dividends

The table displays the monthly dividend distributions for Gilead Sciences, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDec
2024$0.00$0.00$0.77
2023$0.00$0.00$0.75$0.00$0.00$0.75$0.00$0.00$0.75$0.00$0.00$0.75
2022$0.00$0.00$0.73$0.00$0.00$0.73$0.00$0.00$0.73$0.00$0.00$0.73
2021$0.00$0.00$0.71$0.00$0.00$0.71$0.00$0.00$0.71$0.00$0.00$0.71
2020$0.00$0.00$0.68$0.00$0.00$0.68$0.00$0.00$0.68$0.00$0.00$0.68
2019$0.00$0.00$0.63$0.00$0.00$0.63$0.00$0.00$0.63$0.00$0.00$0.63
2018$0.00$0.00$0.57$0.00$0.00$0.57$0.00$0.00$0.57$0.00$0.00$0.57
2017$0.00$0.00$0.52$0.00$0.00$0.52$0.00$0.00$0.52$0.00$0.00$0.52
2016$0.00$0.00$0.43$0.00$0.00$0.47$0.00$0.00$0.47$0.00$0.00$0.47
2015$0.43$0.00$0.00$0.43$0.00$0.00$0.43

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%4.5%
Gilead Sciences, Inc. has a dividend yield of 4.51%, which is quite average when compared to the overall market.
Payout Ratio
20.0%40.0%60.0%80.0%100.0%120.0%42.9%
Gilead Sciences, Inc. has a payout ratio of 42.90%, which is quite average when compared to the overall market. This suggests that Gilead Sciences, Inc. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%NovemberDecember2024FebruaryMarchApril
-25.82%
-4.64%
GILD (Gilead Sciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Gilead Sciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Gilead Sciences, Inc. was 70.83%, occurring on Jun 6, 1994. Recovery took 300 trading sessions.

The current Gilead Sciences, Inc. drawdown is 25.82%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-70.83%Jan 28, 1992596Jun 6, 1994300Aug 11, 1995896
-60.44%Sep 26, 1997237Sep 3, 1998124Mar 4, 1999361
-59.67%Sep 8, 199973Dec 20, 1999169Aug 21, 2000242
-58.8%Jan 29, 1996117Jul 15, 1996298Sep 17, 1997415
-53.46%Sep 26, 200073Jan 9, 200191May 21, 2001164

Volatility

Volatility Chart

The current Gilead Sciences, Inc. volatility is 4.30%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%NovemberDecember2024FebruaryMarchApril
4.30%
3.30%
GILD (Gilead Sciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Gilead Sciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items